Page 42 - Read Online

Carr. Hepatoma Res 2019;5:3 I http://dx.doi.org/10.20517/2394-5079.2018.113 Page 9 of 10

7. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for
unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-71.
8. Llovet JM, Real MI, Montaña X, Planas R, Coll S, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in
patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-9.
9. Zhao M, Xiang P, Jiang H. Transarterial chemoembolization (TACE) with platrinum versus anthracyclenes for hepatocellular
carcinoma: a meta analysis. Int J surg 2018;53:151-8.
10. Xie ZB, Wang XB, Peng YC, Zhu SL, Ma L, et al. Systematic review comparing the safety and efficacy of conventional and drug
eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma. Hepatol Res 2015;45:190-200.
11. Yang DJ, Luo KL, Liu H, Cai B, Tao GQ, et al. Meta-analysis of transcatheter arterial chemoembolization plus radiofrequency
ablation versus transcatheter arterial chemoembolization alone for hepatocellular carcinoma. Oncotarget 2017;8:2960-70.
12. Pommergaard HC, Rostved AA, Adam R, Thygesen LC, Salizzoni M, et al. Locoregional treatments before liver transplantation for
hepatocellular carcinoma: a study from the European Liver Transplant Registry. Transpl Int 2018;31:531-9.
13. Meyer T, Fox R, Ma YT, Ross PJ, James MW, et al. Sorafenib in combination with transarterial chemoembolisation in patients with
unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol
Hepatol 2017;2:565-75.
14. Chao Y, Chung YH, Han G, Yoon JH, Yang J, et al. The combination of transcatheter arterial chemoembolization and sora- fenib
is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial. Int J Cancer
2015;136:1458-67.
15. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC
clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-43.
16. Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, et al. Radioembolization results in longer time to progression and reduced
toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gzastroenterology 2011;140:497-507.
17. Carr BI. Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and
survival data on 65 patients. Liver Transpl 2004;10:S107-10.
18. Salem R, Thurston KG, Carr BI, Goin JE, Geschwind JF. Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J
Vasc Interv Radiol 2002;13:S223-9.
19. Lau WY, Leung WT, Ho S, Leung NW, Chan M, et al. Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial
yttrium-90 microspheres: a phase I and II study. Br J Cancer 1994;70:994-9.
20. Edeline J, Crouzet L, Campillo-Gimenez B, Rolland Y, Pracht M, et al. Selective internal radiation therapy compared with sorafenib
for hepatocellular carcinoma with portal vein thrombosis. Eur J Nucl Med Mol Imaging 2016;43:635-43.
21. Kulik LM, Carr BI, Mulcahy MF, Lewandowski RJ, Atassi B, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular
carcinoma with and without portal vein thrombosis. Hepatology 2008;47:71-81.
22. Spreafico C, Sposito C, Vaiani M, Cascella T, Bhoori S, et al. Development of a prognostic score to predict response to Yttrium-90
radioembolization for hepatocellular carcinoma with portal vein invasion. J Hepatol 2018;68:724-32.
23. Chow PKH, Gandhi M, Tan SB, Khin MW, Khasbazar A, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in
Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol 2018;36:1013-21.
24. Kulik L, Vouche M, Koppe S, Lewandowski RJ, Mulcahy MF, et al. Prospective randomized pilot study of Y90+/- sorafenib as a
bridge to transplantation in hepatocellular carcinoma. J Hepatol 2014;61:309-17.
25. Lobo L, Yakoub D, Picado O, Ripat C, Pendola F, et al. Unresectable hepatocellular carcinoma: radioembolization versus
chemoembolization: a systematic review and meta-analysis. Cardiovasc Intervent Radiol 2016;39:1580-8.
26. Gabr A, Abouchaleh N, Ali R, Vouche M, Atassi R, et al. Comparative study of post-transplant outcomes of hepatocellular carcinoma
patients treated with chemoembolization or radioembolization. Eur J Radiol 2017;93:100-6.
27. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med
2008;359:378-90.
28. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with
advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
29. Peng S, Zhao Y, Xu F, Jia C, Xu Y, et al. An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in
advanced hepatocellular carcinoma. PLoS One 2014;9:e112530.
30. Wu FX, Chen J, Bai T, Zhu SL, Yang TB, et al. The safety and efficacy of transarterial chemoembolization combined with sorafenib
and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma. BMC Cancer 2017;17:645.
31. Liu L, Chen H, Wang M, Zhao Y, Cai G, et al. Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review
and meta-analysis. PLoS One 2014;9:e91124.
32. Zhong JH, Du XK, Xiang BD, Li LQ. Adjuvant sorafenib in hepatocellular carcinoma: a cautionary comment of STORM trial. World
J Hepatol 2016;8:957-60.
33. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable
hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163-73.
34. Bruix J, Qin S, Merle P, Granito A, Huang YH, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on
sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389:56-66.
35. Refolo MG, D’Alessandro R, Lippolis C, Carella N, Cavallini A, et al. IGF-1R tyrosine kinase inhibitors and vitamin K1 enhance the
antitumor effects of regorafenib in HCC cell lines. Oncotarget 2017;8:103465-76.
36. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, et al. Nivolumab in patients with advanced hepatocellular carcinoma
(CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-502.
37. Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, et al. Cabozantinib in patients with advanced and progressing